NKTR - Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test
2024-04-10 00:29:16 ET
Summary
- Nektar Therapeutics' rezpegaldesleukin is now in two phase 2 studies, one in atopic dermatitis and one in alopecia areata.
- The phase 1b data in atopic dermatitis show promise, and a 400-patient phase 2 study in that indication will allow NKTR to examine if the drug indeed has value.
- I give the phase 2 atopic dermatitis study a good chance of success, but there will be a comparison to approved competitors.
- NKTR has a catalyst in 2024 from another pipeline member, NKTR-255, with interim data from the Javelin Bladder Medley study expected in H2'24.
...
Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test